ClinicalTrials.gov (NIH): A Study of Retatrutide (LY3437943) in Participants With Overweight or Obesity (TRIUMPH-1 details)
Who Benefits Most from GLP-1
Discover the potential of Compounded Semaglutide to support your health journey
Emily Kirby oversees our weight loss medications so that you receive an FDA-approved product, the appropriate dosage, and personalized, ongoing care and support
The patients who maintained the most weight loss shared common traits: they had made significant dietary changes , increased physical activity, and often used a structured tapering approach rather than stopping abruptly
Peripheral infusion of GLP-1 decreases food consumption and increases satiety in both normal and obese individuals, presumably by interaction with sensory neurones in the gastrointestinal tract or hepatoportal region (Trapp and Brierley 2022)